Premium
Exosomes and Nanoengineering: A Match Made for Precision Therapeutics
Author(s) -
Tran Phuong H. L.,
Xiang Dongxi,
Tran Thao T. D.,
Yin Wang,
Zhang Yumei,
Kong Lingxue,
Chen Kuisheng,
Sun Miaomiao,
Li Yong,
Hou Yingchun,
Zhu Yimin,
Duan Wei
Publication year - 2020
Publication title -
advanced materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.707
H-Index - 527
eISSN - 1521-4095
pISSN - 0935-9648
DOI - 10.1002/adma.201904040
Subject(s) - nanoengineering , nanomedicine , microvesicles , aptamer , nanotechnology , drug delivery , targeted drug delivery , computational biology , biomimetic materials , materials science , biology , nanoparticle , microrna , microbiology and biotechnology , biochemistry , gene
Targeted exosomal delivery systems for precision nanomedicine attract wide interest across areas of molecular cell biology, pharmaceutical sciences, and nanoengineering. Exosomes are naturally derived 50–150 nm nanovesicles that play important roles in cell‐to‐cell and/or cell‐to‐tissue communications and cross‐species communication. Exosomes are also a promising class of novel drug delivery vehicles owing to their ability to shield their payload from chemical and enzymatic degradations as well as to evade recognition by and subsequent removal by the immune system. Combined with a new class of affinity ligands known as aptamers or chemical antibodies, molecularly targeted exosomes are poised to become the next generation of smartly engineered nanovesicles for precision medicine. Here, recent advances in targeted exosomal delivery systems engineered by aptamer for future strategies to promote human health using this class of human‐derived nanovesicles are summarized.